Overview

A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and paclitaxel combination therapy in patients with relapsed or refractory extensive stage small cell lung cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
STCube, Inc.
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel